Overall, our findings contribute to the growing body of evidence describing the indispensable role of Nrf2 in preserving physiological GSH levels within cortical astrocytes, thereby supporting the rationale for Nrf2-targeted drug development in neurological disorders [89,90,91], such as Parkinson’s Disease (PD), Alzheimer’s Disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease (HD), and Multiple Sclerosis (MS) (reviewed in [13,92]), where oxidative stress is a crucial mechanism leading to cellular injury [93]. This evidence concerns the gene NFE2L2 and early-onset autosomal dominant Alzheimer disease.